Neurolief Secures $6M Investment to Expand Brain Neuromodulation Therapy Post FDA Approval

Neurolief Secures Investment to Enhance Mental Health Care

Neurolief, an innovative company in the realm of medical technology, has recently secured a substantial investment of $6 million from BrainsWay Ltd. This funding comes on the heels of the FDA's approval of Neurolief's Proliv™Rx brain neuromodulation system, a significant milestone that expands treatment options for individuals suffering from depression.

Addressing a Critical Need in Mental Health

Mental health issues, particularly depression, continue to be a growing concern in the United States. According to recent data, millions of adults suffer from depressive disorders, and a significant portion of these individuals do not respond adequately to traditional antidepressant therapies. While alternative treatment options do exist, most require patients to visit specialized clinics, leading to barriers such as logistical challenges, referral delays, and inadequate infrastructure that restrict access to care.

With the rising demand for accessible, effective treatment options, Neurolief's Proliv™Rx aims to fill this gap. This pioneering therapy is designed for at-home use, thereby enabling patients to receive care in a more convenient setting under the supervision of healthcare professionals. The FDA approval, granted in December 2025, marks Proliv™Rx as the first and only brain neuromodulation system that can be used at home for patients who have not found relief from at least one antidepressant.

The Mechanics of Proliv™Rx

Proliv™Rx works by utilizing advanced neuromodulation technology to address the intricacies of depression. The system is prescribed by a physician, who provides necessary oversight while patients self-administer the treatment in their own homes. This hybrid approach strives to maintain high standards of care while broadening access to advanced therapeutic options for those unable to visit specialized centers.

Scott Drees, the Chief Executive Officer of Neurolief, commented, "This investment enhances our ability to bring clinically validated brain stimulation therapy to patients who have not achieved adequate improvement with antidepressants. Proliv™Rx was developed to close a critical access gap at a pivotal point in the depression care journey."

The focus on value-based care in today’s healthcare landscape emphasizes the importance of efficiently identifying and treating high-need patients. Owen Muir, MD, Chief Medical Officer at Neurolief, highlighted this shift: "Proliv™Rx was designed to deliver clinically supervised brain neuromodulation in the home. This enables clinicians to reach patients faster and reduce treatment delays."

About Neurolief and BrainsWay

Neurolief is committed to revolutionizing mental health care through its pioneering non-invasive neuromodulation therapies, addressing the pressing need for effective treatment options in mental health and neurological disorders.

BrainsWay, the investor behind this strategic move, is recognized for spearheading advancements in noninvasive neurostimulation treatments. Their proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology has garnered multiple FDA clearances, underscoring their commitment to improving health outcomes across various mental health disorders.

With the additional funding secured, Neurolief is poised to enhance its outreach and deliver a lifeline to those grappling with inadequate treatment responses in their journey toward mental wellness. The company aims to streamline the deployment of Proliv™Rx and eventually increase accessibility and acceptance of neuromodulation therapy in the treatment landscape for depression.